Browsing by Author "Hosal, Sefik"

Now showing 1 - 4 of 4

Editorial: Quality Assurance and Workflow Optimization for the Diagnosis and Treatment of Head and Neck Cancer
(Frontiers Media Sa, 2024) Elicin, Olgun; Hosal, Sefik
[No Abstract Available]
Citation - WoS: 60
Citation - Scopus: 66
European Head and Neck Society Recommendations for Head and Neck Cancer Survivorship Care
(Elsevier, 2022) Verdonck-de Leeuw, Irma; Hoşal, Ali Şefik; Dawson, Camilla; Licitra, Lisa; Eriksen, Jesper Grau; Hosal, Sefik; Singer, Susanne; Leemans, C. Rene; Hoşal, Ali Şefik; Surgical Sciences; Surgical Sciences
Survivors of head and neck cancer can experience long-term consequences of the cancer and subsequent treatments even after the cancer has resolved. Increasingly clinicians are aware of the social, psychological, financial, and emotional impacts of these cancers, in addition to the support required for the physical symptoms. This review provides recommendations on the long-term management and support required for survivors of head and neck cancer in the European healthcare setting.
Citation - WoS: 8
Citation - Scopus: 10
Human Laryngeal Squamous Cell Carcinoma Cell Line Release of Endogenous Anandamide and 2-Arachidonoylglycerol, and Their Antiproliferative Effect Via Exogenous Supplementation: an in Vitro Study
(Springer, 2022) Onay, Ovsen; Kose, Sevil; Suslu, Nilda; Korkusuz, Petek; Nemutlu, Emirhan; Aydin, Canset; Hosal, Sefik
The level of the major endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are altered in several types of carcinomas, and are known to regulate tumor growth. Thusly, this study hypothesized that the HEp-2 human laryngeal squamous cell carcinoma (LSCC) cell line releases AEA and 2-AG, and aimed to determine if their exogenous supplementation has an anti-proliferative effect in vitro. In this in vitro observational study a commercial human LSCC cell line (HEp-2) was used to test for endogenous AEA and 2-AG release via liquid chromatography-tandem mass spectrometry (LC-MS/MS). The anti-proliferative effect of AEA and 2-AG supplementation was evaluated via WST-1 proliferation assay. It was observed that the HEp-2 LSCC cell line released AEA and 2-AG; the median quantity of AEA released was 15.69 ng mL(-1) (range: 14.55-15.95 ng mL(-1)) and the median quantity of 2-AG released was 2.72 ng (-1) (range: 2.67-2.74 ng mL(-1)). Additionally, both AEA and 2-AG exhibited an anti-proliferative effect. The anti-proliferative effect of 2-AG was stronger than that of AEA. These findings suggest that AEA might function via a CB1 receptor-independent pathway and that 2-AG might function via a CB2-dependent pathway. The present findings show that the HEp-2 LSCC cell line releases the major endocannabinoids AEA and 2-AG, and that their supplementation inhibits tumor cell proliferation in vitro. Thus, cannabinoid ligands might represent novel drug candidates for laryngeal cancers, although functional in vivo studies are required in order to validate their potency.
Transoral Robotic Surgery (TORS) for Head and Neck Cancer in the Elderly Population: Functional Outcomes, Survival, and Complications
(Wiley, 2025) Pamuk, Erim; Beharry, Avinash; Lambercy, Karma; Dalla-Vale, Margaux; Wahler, Nina; Hosal, Sefik; Simon, Christian
Objective: To compare functional and oncologic outcomes in elderly (>= 70 years) and nonelderly (< 70 years) patients after transoral robotic surgery (TORS). Methods: A retrospective chart review was conducted on 114 patients who underwent TORS for head and neck squamous cell carcinoma between 2012 and 2022. Patient and tumor characteristics, perioperative details, complications, and survival parameters were analyzed. Swallowing function was assessed using the Functional Outcome Swallowing Scale (FOSS). Results: Of the 114 patients, 37 (32.5%) were elderly, and 77 (67.5%) were nonelderly. Elderly patients had higher comorbidity scores (p < 0.001). Oropharyngeal and oral cavity primaries were more common in the nonelderly group, whereas laryngeal primaries predominated in elderly patients (p < 0.01). Complication rates were higher in nonelderly (37.6%) than in elderly (18.9%) patients, though not statistically significant (p = 0.07). In elderly patients, FOSS scores showed no significant change preoperatively, postoperatively (< 3 months), or at the last follow-up (median 36 months). The nonelderly group experienced worse early postoperative FOSS scores compared to baseline but showed significant improvement, returning to preoperative levels by the last follow-up. Nonelderly patients had better FOSS scores at last follow-up compared to elderly patients (p = 0.014). Overall and recurrence-free survival outcomes were better in the nonelderly group, but disease-specific survival rates were comparable. Conclusion: Despite higher comorbidity rates in the elderly, TORS demonstrated favorable complication rates in the elderly population. Swallowing function returned to baseline after 3 months in both groups. TORS appears safe for elderly patients with comparable oncologic outcomes.